Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- The prevalence of diabetes was 15.8 percent among U.S. adults during August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.
Jane A. Gwira, M.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the National Health and Nutrition Examination Survey to examine the prevalence of diagnosed, undiagnosed, and total diabetes (excluding gestational diabetes) among U.S. adults during August 2021 to August 2023.
The researchers found that the prevalence of total diabetes was 15.8 percent, and the prevalence rates of diagnosed and undiagnosed diabetes were 11.3 and 4.5 percent, respectively, among U.S. adults during August 2021 to August 2023. Men had a higher prevalence of total and diagnosed diabetes than women (18.0 and 12.9 percent versus 13.7 and 9.7 percent). With age and with increasing weight status, there was an increase in the prevalence of total, diagnosed, and undiagnosed diabetes. Between 1999-2002 and August 2021 to August 2023, there was an increase in the age-adjusted prevalence of total and diagnosed diabetes.
"Slightly more than one-quarter of adults with diabetes had undiagnosed diabetes," the authors write. "Continued monitoring of both diagnosed and undiagnosed diabetes will provide essential information about the prevalence of diabetes in adults in the United States."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-07 06:00
Read more
- FDA Grants Fast Track Designation For Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD)
- Election Stressing You Out? An Expert Has Coping Tips
- Prenatal Cannabis Exposure May Impact Executive Function, Behavior at Age 5 Years
- Frequent Social Media Use Harmful for High School Students
- Abortions Have Increased, Even in States With Bans, Report Finds
- Monthly News Roundup - October 2024
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions